Janux Therapeutics, Inc. (JANX) fundamentals score
Janux Therapeutics is an innovative clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms.
Pharmaceutical Preparations · Healthcare · Listed on NASDAQ
Overall: 6.3 out of 10, Mixed fundamentals
- Growth: 6.7/10
- Profitability: 3.3/10
- Financial health: 8.0/10
- Earnings quality: 7.6/10
- Valuation: 7.0/10
Scores are calculated from Janux Therapeutics, Inc.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10